Adverse Event Reporting
| VAERS ID | 1969999 |
|---|---|
| Gender | Female |
| Age | |
| StateCode | FR |
| Pharmaceutical Company | PFIZER\BIONTECH |
| Lot Number | ER2659 |
| Number of vaccinations | 1 |
| Vaccinated | 2008-12-16 |
| Onset | 2021-03-01 |
| Condition | Permanent Disability |
Symptoms
- Cognitive disorder
- Amnesia
- Dementia
- Patient elopement
Current Illness
Preexisting Conditions
Medical History/Concurrent Conditions: Atrial fibrillation; Dementia; Hypertension
Other Medications
EBIXA; CARDICOR
Previous Vaccinations
Allergies
Laboratory Data
Write-up
wandering; major memory loss; cognitive deterioration; great increase in her dementia symptoms; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP and Physician) from the regulatory authority-WEB.
An 82 year-old female patient received bnt162b2 (COMIRNATY), administration date 03Mar2021 (Lot number: ER2659) as dose 1, single for covid-19 immunisation; warfarin (WARFARIN), since 16Dec2008 (ongoing) (Batch/Lot number: unknown) at as per international normalised ratio (inr) for atrial fibrillation.
Relevant medical history included: "Dementia, mild" (unspecified if ongoing); "Atrial fibrillation" (unspecified if ongoing); "Hypertension, mild" (unspecified if ongoing).
Concomitant medication(s) included: EBIXA taken for dementia, start date: 05Nov2017 (ongoing); CARDICOR taken for atrial fibrillation, start date: 25Aug2008 (ongoing).
The following information was reported: PATIENT ELOPEMENT (disability) with onset Mar2021, outcome "unknown", described as "wandering"; AMNESIA (disability) with onset Mar2021, outcome "unknown", described as "major memory loss"; COGNITIVE DISORDER (disability) with onset Mar2021, outcome "unknown", described as "cognitive deterioration"; DEMENTIA (disability) with onset Mar2021, outcome "unknown", described as "great increase in her dementia symptoms".
After the first dose, in Mar2021, the patient experienced cognitive deterioration.
This was reported as a rapid deterioration in the patient cognitive abilities, with a great increase in her dementia symptoms including major memory loss and wandering.
The action taken for warfarin was unknown.
No follow-up attempts are possible.
No further information is expected.